Send to

Choose Destination
See comment in PubMed Commons below
Ocul Immunol Inflamm. 2012 Apr;20(2):86-90. doi: 10.3109/09273948.2011.645989.

Interferon alpha 2b in the treatment of uveitic cystoid macular edema.

Author information

  • 1Wilmer Eye Institute, Ophthalmology, Baltimore, Maryland, United States.



To determine the efficacy of interferon alpha 2b in the treatment of refractory, uveitic cystoid macular edema (CME).


Retrospective chart review of 4 patients attending the uveitis clinic at the Casey Eye Institute, Oregon Health & Science University.


All 4 patients had uveitis and refractory CME, resistant to a variety of immunosuppressants. All patients, except one with severe scleral thinning, had tried and failed therapy with locally injected corticosteroids. Treatment with systemic interferon alpha 2b produced dramatic improvement in CME (central macular thickness: 563 to 267 ┬Ám, p = .002) and visual acuity (logMAR: +0.81 to +0.45, p = .0004) in all 4 cases. All patients have been able to reduce the interferon dosage, but none has discontinued it completely. All patients had some mild adverse response that did not necessitate stopping therapy.


Interferon alpha 2b is an effective option to treat refractory CME secondary to uveitis.

Comment in

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Write to the Help Desk